 |
245 Diseases |  |
389 Trials |
|
389 Trials |  |
11400 News |  |
| «12...1213141516171819202122...143144» |
- | Journal, Tumor mutational burden, BRCA Biomarker, PARP Biomarker, PD(L)-1 Biomarker, Metastases: Establishment of patient-derived tumor organoids to functionally inform treatment decisions in metastatic colorectal cancer. (Pubmed Central) - Jul 3, 2023
Using CRC as a model, we have designed and validated a clinically applicable methodology to potentially inform clinical decisions with functional data. Undoubtedly, further larger analyses are needed to improve methodology success rates and propose suitable treatment strategies for mCRC patients.
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical data, Journal, Metastases: Impact of primary tumor side on clinical outcomes of first-line cetuximab plus FOLFOX-4 in RAS wild-type metastatic colorectal cancer. (Pubmed Central) - Jul 3, 2023
Undoubtedly, further larger analyses are needed to improve methodology success rates and propose suitable treatment strategies for mCRC patients. Aim: To examine the impact of tumor sidedness on clinical outcomes in Chinese patients with metastatic colorectal cancer treated with folinic acid/fluorouracil/oxaliplatin (FOLFOX-4)
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal, PD(L)-1 Biomarker, IO biomarker: EGFR Inhibition by Cetuximab Modulates Hypoxia and IFN Response Genes in Head and Neck Squamous Cell Carcinoma. (Pubmed Central) - Jul 2, 2023
While the hypoxic and immunosuppressive TME of HNSCC has been well described, comprehensive evaluation of the immune cell components and signaling pathways contributing to immunotherapy resistance has been poorly characterized. We further identified additional molecular determinants and potential therapeutic targets of the hypoxic TME to fully leverage currently available targeted therapies that can be administered with immunotherapy.
- || What do you think about folfoxiri Plus cetuximab plus dabrafenib (Twitter) - Jun 29, 2023
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer
Estimado doctor. ¿En el caso de cáncer de pulmón Encorafenib está financiado? Mi padre tiene cáncer de colon con mutación BRAF V600E y para su tratamiento de Encorafenib + Cetuximab deberá pagar casi 6.000 € mensuales (4 comprimidos diarios) por el primero de ellos. (Twitter) - Jun 29, 2023
- | fosifloxuridine nafalbenamide (NUC-3373) / NuCana
Trial completion date, Trial primary completion date, Combination therapy: NuTide:302: A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment (clinicaltrials.gov) - Jun 29, 2023
P1/2, N=225, Recruiting, Sponsor: NuCana plc
We further identified additional molecular determinants and potential therapeutic targets of the hypoxic TME to fully leverage currently available targeted therapies that can be administered with immunotherapy. Trial completion date: Jun 2023 --> Nov 2023 | Trial primary completion date: Jun 2023 --> Nov 2023
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Cetuximab and 5-fluorouracil (5-FU) in patients with advanced cutaneous squamous cell carcinoma: a retrospective data analysis (Hall E) - Jun 28, 2023 - Abstract #ADO2023ADO_147;
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Improved Therapeutic Delivery Targeting Clinically Relevant Orthotopic Human Pancreatic Tumors Engrafted in Immunocompromised Pigs Using Ultrasound-Induced Cavitation: A Pilot Study. (Pubmed Central) - Jun 28, 2023
Cavitation increased the intra-tumor concentrations of Cetuximab, gemcitabine, and paclitaxel by 477%, 148%, and 193%, respectively, compared to tumors that were not targeted with ultrasound in the same animals. Together, these data show that ultrasound-mediated cavitation, when delivered in combination with gas-entrapping particles, improves therapeutic delivery in pancreatic tumors under clinically relevant conditions.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Enhancing Anticancer Efficacy of Chemotherapeutics Using Targeting Ligand-Functionalized Synthetic Antigen Receptor-Mesenchymal Stem Cells. (Pubmed Central) - Jun 28, 2023
Biodistribution studies revealed a six-fold higher retention of EGFR-targeted MSCs than non-targeted MSCs. Based on these results, we conclude that targeting ligand functionalization could be used to enhance the concentration of therapeutic MSC constructs at the tumor tissue and to achieve improved antitumor response.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Cetuximab for Immunotherapy-Refractory/Ineligible Cutaneous Squamous Cell Carcinoma. (Pubmed Central) - Jun 28, 2023
Cetuximab immediately after ICI failure yielded particularly fast, durable responses. If confirmed, this could be the preferred therapy following ICI failure.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion date, Metastases: FAMOSO: Accelerated Modulated Fractionation (SIB-IMRT) for Head and Neck District (clinicaltrials.gov) - Jun 28, 2023
P2, N=10, Recruiting, Sponsor: European Institute of Oncology
If confirmed, this could be the preferred therapy following ICI failure. Trial completion date: Dec 2022 --> Dec 2023
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen, Takeda
Journal, Metastases: Associations between AI-assisted tumor amphiregulin and epiregulin IHC and outcomes from anti-EGFR therapy in the routine management of metastatic colorectal cancer. (Pubmed Central) - Jun 26, 2023
High tumor AREG/EREG expression was associated with superior survival outcomes from anti-EGFR therapy in mCRC, including in right PTL disease. AREG/EREG IHC assessment could aid therapeutic decisions in routine practice.
- || Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
P2 data, Journal, Metastases: FOLFOXIRI Plus Cetuximab or Bevacizumab as First-Line Treatment of BRAF-Mutant Metastatic Colorectal Cancer: The Randomized Phase II FIRE-4.5 (AIO KRK0116) Study. (Pubmed Central) - Jun 23, 2023
FOLFOXIRI plus cetuximab does not induce a higher ORR when compared with FOLFOXIRI plus bevacizumab in first-line treatment of BRAF-mutant mCRC. Bevacizumab-based chemotherapy remains the preferable first-line treatment of patients with BRAF-mutant mCRC.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date, Surgery, Metastases: Radiation Therapy With or Without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer (clinicaltrials.gov) - Jun 23, 2023
P3, N=703, Active, not recruiting, Sponsor: Radiation Therapy Oncology Group
Bevacizumab-based chemotherapy remains the preferable first-line treatment of patients with BRAF-mutant mCRC. Trial primary completion date: Dec 2024 --> Sep 2023
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed: Stereotactic Radiotherapy Combined With Chemotherapy or Not for Treatment of Oligometastases in HNSCC (clinicaltrials.gov) - Jun 22, 2023
P2, N=78, Active, not recruiting, Sponsor: Groupe Oncologie Radiotherapie Tete et Cou
Trial primary completion date: Dec 2024 --> Sep 2023 Recruiting --> Active, not recruiting
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Cetuximab enhances radiosensitivity of esophageal squamous cell carcinoma cells by G2/M?cycle arrest and DNA repair delay through inhibiting p-EGFR and p-ERK. (Pubmed Central) - Jun 20, 2023
These results indicate the potential for use of cetuximab as an effective radiosensitizer in ESCC. Cetuximab promotes G2/M?cycle arrest and reduces DSB repair, as well as inhibiting EGFR and downstream ERK pathways in ESCC.
- || Cyramza (ramucirumab) / Eli Lilly, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Review, Journal: Optimizing the dosing regimen of cetuximab and ramucirumab using the model-informed drug development paradigm. (Pubmed Central) - Jun 20, 2023
Eli Lilly and Company (Lilly) participated in the Pilot Program to seek agency alignment to enhance the initial approved dosing regimens of cetuximab (Erbitux; Eli Lilly and Company, Indianapolis, Indiana) and ramucirumab (Cyramza; Eli Lilly and Company, Indianapolis, Indiana) without conducting additional clinical trials. Here we describe the overall MIDD strategy at Lilly, the process with the FDA, and the impact of implementing the approach.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Stivarga (regorafenib) / Bayer
Journal, Circulating tumor DNA, Metastases: Mutational evolution after chemotherapy-progression in metastatic colorectal cancer revealed by circulating tumor DNA analysis. (Pubmed Central) - Jun 19, 2023
The number of mutations revealed by ctDNA sequencing increased during disease progression in mCRC. Clonal heterogeneity increased after chemotherapy progression, and pathways involved were affected by chemotherapy regimens.
- | Keytruda (pembrolizumab) / Merck (MSD)
Journal, HEOR, Mismatch repair, Microsatellite instability, Cost-effectiveness, Cost effectiveness, Metastases: Cost-effectiveness of pembrolizumab in first-line for microsatellite-instability-high or mismatch-repair-deficient metastatic colorectal cancerF. (Pubmed Central) - Jun 19, 2023
Clonal heterogeneity increased after chemotherapy progression, and pathways involved were affected by chemotherapy regimens. Pembrolizumab obtained a cost per month progression-free survival gained ranged from 6471
- | Trial completion date, Trial primary completion date, Metastases: SU2C ACT3: Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer (clinicaltrials.gov) - Jun 18, 2023
P3, N=500, Recruiting, Sponsor: Massachusetts General Hospital
Pembrolizumab obtained a cost per month progression-free survival gained ranged from 6471 Trial completion date: Feb 2023 --> Apr 2026 | Trial primary completion date: Feb 2022 --> Apr 2025
- | brivanib alaninate (BMS-582664) / ZAI Lab
Journal, Metabolomic study, Metastases: Clinical and metabolomic characterization of Brivanib-Induced hypertension in metastatic colorectal cancer. (Pubmed Central) - Jun 17, 2023
TKI-induced hypertension was not associated with clinical benefit in metastatic CRC. We have identified changes in the metabolome that are associated with the development of worsening brivanib-induced hypertension that may be useful in future efforts of characterizing this toxicity.
- ||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer
Clinical, Surgery: New @ALLIANCE_org A022004 trial led by .@RonaYaeger @MSKCancerCenter compares treatment w/encorafenib & cetuximab to usual care to reduce chance of cancer recurrence after standard surgery & chemotherapy in pts w/BRAF-mutated stage IIB-III #coloncancer: https://t.co/F1Oxrw98ah (Twitter) - Jun 16, 2023
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Multi-Functional NK Cell-Engaging Antibodies Targeting EGFR and NKp30 Elicit Efficient Tumor Cell-Killing and Pro-Inflammatory Cytokine Release () - Jun 15, 2023 - Abstract #IOSUMMITEUROPE2023IO_SUMMIT_EUROPE_56;
Combined with a humanized Fab version of Cetuximab for tumor targeting, resulting NK cell engagers (NKCEs) trigger potent NK cell-mediated killing of EGFR-overexpressing tumor cells. By modulating valencies of incorporated binders as well as via engineering the spatial orientation of individual paratopes, killing capacities of constructed NKCEs can be augmented significantly.
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono, Torisel (temsirolimus) / Pfizer
Trial completion date, Trial primary completion date, Combination therapy, Metastases: Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease (clinicaltrials.gov) - Jun 15, 2023
P1, N=155, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
By modulating valencies of incorporated binders as well as via engineering the spatial orientation of individual paratopes, killing capacities of constructed NKCEs can be augmented significantly. Trial completion date: Mar 2023 --> Mar 2024 | Trial primary completion date: Mar 2023 --> Mar 2024
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer, Mektovi (binimetinib) / Ono Pharma, Pierre Fabre, Pfizer
Enrollment open: NeoBRAF: Neoadjuvant Encorafenib, Binimetinib and Cetuximab for Patients With BRAF V600E Mutated/pMMR Localized Colorectal Cancer (clinicaltrials.gov) - Jun 15, 2023
P2, N=48, Recruiting, Sponsor: AIO-Studien-gGmbH
Trial completion date: Mar 2023 --> Mar 2024 | Trial primary completion date: Mar 2023 --> Mar 2024 Not yet recruiting --> Recruiting
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Yervoy (ipilimumab) / Ono Pharma, BMS
Trial completion, Metastases: Ipilimumab, Cetuximab, and Intensity-Modulated Radiation Therapy in Treating Patients With Previously Untreated Stage III-IVB Head and Neck Cancer (clinicaltrials.gov) - Jun 15, 2023
P1, N=19, Completed, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- ||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer
Preclinical: 🔥Antitumor Efficacy of Dual Blockade with Encorafenib & Cetuximab with CTx in Human BRAFV600E-mCRC @CCR_AACR https://t.co/PeIO5T2h85 👉interesting preclinical study to evaluate the best combination for targeted and chemotherapies 👇supports BREAKWATER phs-III @myESMO @OncoAlert (Twitter) - Jun 14, 2023
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer
Journal, Combination therapy: Antitumor efficacy of dual blockade with encorafenib plus cetuximab in combination with chemotherapy in human BRAFV600E mutant colorectal cancer. (Pubmed Central) - Jun 14, 2023
Active, not recruiting --> Completed These results support the combination of cytotoxic chemotherapy and molecular targeted therapy as a promising therapeutic approach in the first-line treatment of BRAFV600E mCRC.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Evaluating the Time Toxicity of Cancer Treatment in the CCTG CO.17 Trial. (Pubmed Central) - Jun 14, 2023
Such data can supplement traditional survival end points in RCTs. Further work should refine and validate the measure prospectively.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Negative correlation between acetyl-CoA acyltransferase 2 and cetuximab resistance in colorectal cancer. (Pubmed Central) - Jun 13, 2023
ACAA2 expression is related to Kras mutation and demonstrates a prognostic role in CRC patients with Kras mutation. Thus, ACAA2 is a potential target in CRC with Kras mutation.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion date, Trial primary completion date, Metastases: CETIDYL: Cetuximab as Salvage Therapy in Patients With Neo Wild-type RAS/RAF Metastatic Colorectal Cancer With Liver Metastases. (clinicaltrials.gov) - Jun 12, 2023
P2, N=72, Recruiting, Sponsor: GCS IHFB Cognacq-Jay
Thus, ACAA2 is a potential target in CRC with Kras mutation. Trial completion date: Jul 2023 --> Jul 2024 | Trial primary completion date: Apr 2023 --> Apr 2024
- |||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer
Clinical: Excited to announce that A022004 randomized trial of adjuvant encorafenib + cetuximab vs usual care after standard rx for BRAF V600E stage III, high risk stage II colon cancer is now activated and available to all NCTN sites. @Alliance_org @EileenMOReilly @smitha42 @SyedKazmiMD (Twitter) - Jun 11, 2023
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen, Takeda
Journal: Preventing skin toxicities induced by EGFR inhibitors by topically blocking drug-receptor interactions. (Pubmed Central) - Jun 11, 2023
Specific small molecules were topically applied and were delivered via a slow-release system derived from biodegradable nanoparticles that penetrate the hair follicles and sebaceous glands, within which EGFR is highly expressed. Our approach has the potential to reduce skin toxicity caused by EGFR inhibitors.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Preclinical, Journal: Thyroarytenoid Oxidative Metabolism and Synaptic Signaling Dysregulation in the Female Pink1-/- Rat. (Pubmed Central) - Jun 9, 2023
Data presented here are useful for identifying biological pathways that may underlie the mechanisms of peripheral dysfunction including neuromuscular synaptic transmission to the TA muscle. These experimental biomarkers have the potential to be targeted as sites for improving the treatment for hypophonia in early-stage PD.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: EpEX, the soluble extracellular domain of EpCAM, resists cetuximab treatment of EGFR-high head and neck squamous cell carcinoma. (Pubmed Central) - Jun 9, 2023
The EpEX-activated Cmab resistance in HNSC is potentially mediated by the EGFR-ERK signaling pathway and the EpCAM cleavage-induced nuclear translocation of EpICD. High expression and cleavage of EpCAM are potential biomarkers for predicting the clinical efficacy and resistance to Cmab.
- || ASP3082 / Astellas
Enrollment change, Metastases: A Study of ASP3082 in Adults With Previously Treated Solid Tumors (clinicaltrials.gov) - Jun 8, 2023
P1, N=356, Recruiting, Sponsor: Astellas Pharma Inc
High expression and cleavage of EpCAM are potential biomarkers for predicting the clinical efficacy and resistance to Cmab. N=260 --> 356
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P4 trial, Real-world evidence, Real-world, Metastases: Survival Benefit of Compound Kushen Injection in the Treatment of Advanced Colorectal Cancer (clinicaltrials.gov) - Jun 8, 2023
P4, N=318, Recruiting, Sponsor: Guang'anmen Hospital of China Academy of Chinese Medical Sciences
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal, Patient reported outcomes: Patient-reported outcomes in immunotherapy for head and neck cancer. (Pubmed Central) - Jun 8, 2023
N=260 --> 356 Despite increasing patient-reported toxicity, checkpoint inhibitor monotherapy and combination therapy were associated with similar transient improvements, then worsening, of QOL in patients with HNSCC.
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen, Takeda
Review, Journal, IO biomarker, Metastases: Beyond EGFR inhibitors in advanced colorectal cancer: Targeting BRAF and HER2. (Pubmed Central) - Jun 7, 2023
This review will highlight key clinical studies that support the rational use of v-Raf murine sarcoma viral oncogene homolog B1 (BRAF) and HER2-targeted therapies, often in combination with other targeted agents, cytotoxic chemotherapy, and immune checkpoint inhibitors. We discuss current challenges with BRAF and HER2-targeted therapies in metastatic colorectal cancer and potential opportunities for improvement.
- | Bosulif (bosutinib) / Pfizer, Erbitux (cetuximab) / Eli Lilly, EMD Serono, Tafinlar (dabrafenib) / Novartis
Journal, Tumor mutational burden, PD(L)-1 Biomarker, IO biomarker: EPAS1/HIF-2? Acts as an Unanticipated Tumor-Suppressive Role in Papillary Thyroid Carcinoma. (Pubmed Central) - Jun 7, 2023
EPAS1/HIF-2? contributed to anti-tumor immunity by promoting CD8+ T cell infiltration and inhibiting PD-L1 expression in PTC.
- || opnurasib (JDQ443) / Novartis
Trial completion date, Trial primary completion date, Metastases: KontRASt-03: Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation (clinicaltrials.gov) - Jun 7, 2023
P1/2, N=346, Recruiting, Sponsor: Novartis Pharmaceuticals
contributed to anti-tumor immunity by promoting CD8+ T cell infiltration and inhibiting PD-L1 expression in PTC. Trial completion date: Aug 2025 --> Jun 2027 | Trial primary completion date: Jun 2025 --> May 2027
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Biomarker, Journal, Tumor microenvironment: Comprehensive characterization of tumor microenvironment in colorectal cancer via molecular analysis. (Pubmed Central) - Jun 6, 2023
Importantly, we established a simple gene classifier for accurate identification of each CCCRC subtype. Collectively our integrative analysis ultimately established a holistic framework to thoroughly dissect the TME of CRC, and the CCCRC classification system with high biological interpretability may contribute to biomarker discovery and future clinical trial design.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Herceptin (trastuzumab) / Roche
Journal, Virus specific T cells: Comparison of methods generating antibody-epitope conjugates for targeting cancer with virus-specific T cells. (Pubmed Central) - Jun 5, 2023
Therefore, screening of multiple protease cleavage sites and epitopes attached to the antibody is necessary. Taken together, our data demonstrated that multiple AECs could sensitize cancer cells to virus-specific T cells.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Sequential administration of PD?1 inhibitor and cetuximab causes pneumonia. (Pubmed Central) - Jun 5, 2023
Severe drug-induced lung injury (DLI) has been reported to be associated with sequential administration of osimertinib, a third-generation tyrosine kinase inhibitor, following a programmed cell death ligand 1 (PD-L1) inhibitor...The present study conducted a retrospective review of the medical records of a total of 179 patients with head and neck cancer who had received treatment with cetuximab and/or a PD-1 inhibitor (nivolumab or pembrolizumab) at Chiba University Hospital (Chiba, Japan) between September 2014 and December 2020...Prior use of ICI was not associated with any increase in the risk of DLI. DLI is seen frequently in patients receiving sequential PD-1 inhibitor and anti-EGFR antibody therapy.
- | BCA101 / Biocon
Journal, PD(L)-1 Biomarker, IO biomarker: BCA101 is a Tumor-Targeted Bifunctional Fusion Antibody that Simultaneously Inhibits EGFR and TGF-? Signalling to Durably Suppress Tumor Growth. (Pubmed Central) - Jun 5, 2023
DLI is seen frequently in patients receiving sequential PD-1 inhibitor and anti-EGFR antibody therapy. In addition, BCA101 inhibited differentiation of na
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Enrollment change: SBRT With Cetuximab +/- Docetaxel Followed by Adjuvant Cetuximab +/- Docetaxel in Recurrent, Previously-Irradiated SCCHN (clinicaltrials.gov) - Jun 5, 2023
P2, N=40, Completed, Sponsor: Heath Skinner
In addition, BCA101 inhibited differentiation of na Recruiting --> Completed | N=92 --> 40
- || Ibrance (palbociclib) / Pfizer, Erbitux (cetuximab) / Eli Lilly, EMD Serono
I believe that an effective drug / a real positive trial doesn't need complex statistics. It's positive results will be blatantly visible. Plus don't be a pessimist. Palbociclib now costs 5k per month (from 80k per month), Cetuximab cost fell down to 10k per vial recently (Twitter) - Jun 3, 2023
- ||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Should we combine it with Cetuximab in GI malignancies ? (Twitter) - Jun 3, 2023
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Development of a New Method to Evaluate the Biodistribution of Antibodies Using Non-Radioactive Metal Labeling and Inductively Coupled Plasma Mass Spectrometry. (Pubmed Central) - Jun 2, 2023
The assessment of antibody distribution using ICP-MS is a novel alternative to the traditional radiolabeled approach. It facilitates the assessment of antibody distribution in the early stages of drug discovery and accelerates the assessment of target engagement.